3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Ovarian Neoplasms
10
Fallopian Tube Neoplasms
10
Prostatic Neoplasms
7
Carcinoma, Ovarian Epithelial
6
Endometrial Neoplasms
5
Breast Neoplasms
5
Recurrence
3
Pancreatic Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Neoplasm Metastasis
2
Metastatic Castration Resistant Prostate Cancer
2
Lung Neoplasms
2
Carcinoma, Transitional Cell
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related
1
Interventions
pembrolizumab
2
Pemetrexed
2
Paclitaxel
2
Carboplatin
2
nilotinib
1
Palliative Care
1
Laparoscopy
1
Gemcitabine
1
Electrocardiography
1
Educational Status
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Genital Neoplasms, Female
×
rucaparib
×
Clear all
No trials found.